Zobrazeno 1 - 9
of 9
pro vyhledávání: '"S. Peter King"'
Publikováno v:
Bioanalysis. 1:1415-1418
The pharmacokinetic (PK) repeat study sample, selected by the study pharmacokineticist, requires repeat bioanalysis because the concentration is incongruous with drug plasma concentration versus time profile. The inconsistency could be due to a numbe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ebbaeed6b96160234543964b5c65f9c
https://doi.org/10.4155/bio.09.99
https://doi.org/10.4155/bio.09.99
Autor:
Anthony J. DeStefano, Daniel Tang, Jacqueline A. O'Shaughnessy, Marian Kelley, Ajai K. Chaudhary, S. Peter King, Russell Weiner, Douglas M. Fast, C. T. Viswanathan
Publikováno v:
The AAPS Journal. 11:238-241
The Conference Report of the 3rd AAPS/FDA Bioanalytical Workshop (Crystal City III) endorsed the concept that assay methods supporting bioanalytical data in submissions must demonstrate assay reproducibility by using incurred samples. The present Wor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8701cdb5f80696bcc8caa8e767717bdd
https://doi.org/10.1208/s12248-009-9100-9
https://doi.org/10.1208/s12248-009-9100-9
Autor:
Peter E. Grebow, Watson B. Laughton, Y. Nancy Wong, George C. McCormick, Linda N. Hartman, S. Peter King, Donna Simcoe
Publikováno v:
The Journal of Clinical Pharmacology. 39:30-40
A randomized, double-blind, placebo-controlled, ascending-dose study was conducted to evaluate the pharmacokinetic and safety profiles of increasing modafinil doses (200 mg, 400 mg, 600 mg, 800 mg) administered orally over a 7-day period in normal he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4493357a686b5052ca3ed4a0b7da2b38
https://doi.org/10.1177/00912709922007534
https://doi.org/10.1177/00912709922007534
Penetration of dalbavancin into noninfected bone and joint tissues was assessed after an intravenous dose of 20 mg/kg (of body weight) [ 14 C]dalbavancin given to rabbits. Drug-derived radioactivity, determined over 14 days by either liquid scintilla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba38346438416ec1c3511b3fe0b2118
https://europepmc.org/articles/PMC1932505/
https://europepmc.org/articles/PMC1932505/
Autor:
Shashank, Rohatagi, Yongyi, Luo, Liduo, Shen, Zuyu, Guo, Christina, Schemm, Yongqing, Huang, Kelly, Chen, Michael, David, Ruediger, Nave, S Peter, King
Publikováno v:
American journal of therapeutics. 12(3)
Freely circulating, protein unbound, active inhaled corticosteroid (ICS) can cause systemic adverse effects. Desisobutyryl-ciclesonide (des-CIC) is the active metabolite of ciclesonide, an effective, novel ICS for persistent asthma. This study examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::04fb0d09d5b3ca5ddcd1fc0bb7df8aa9
https://pubmed.ncbi.nlm.nih.gov/15891262
https://pubmed.ncbi.nlm.nih.gov/15891262
Autor:
Volker Fischer, Thorir D. Bjornsson, Heidi J. Einolf, José M. Vega, Steven A. Wrighton, Gerald T. Miwa, Scott W. Grimm, John Kao, John S Walsh, Lan Ni, Donald J. Tweedie, R. Scott Obach, J. T. Callaghan, Amy L. Roe, John T. Sullivan, S. Peter King, Anita Shah, Stanley Roberts, James F. McLeod, Fred Snikeris, Lawrence Gan, Gondi N. Kumar
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 31(7)
Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better asse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0734cbabfefaa5652a58511222e971df
https://pubmed.ncbi.nlm.nih.gov/14570779
https://pubmed.ncbi.nlm.nih.gov/14570779
Publikováno v:
Journal of clinical pharmacology. 41(11)
The purpose of this study was to characterize the pharmacokinetics of gemtuzumab ozogamicin (Mylotarg; Wyeth-Ayerst Laboratories, St. Davids, PA) in patients with acute myeloid leukemia (AML) in first relapse. Gemtuzumab ozogamicin is an antibody-che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219cb139008ea9b446346e6908971d6c
https://pubmed.ncbi.nlm.nih.gov/11697753
https://pubmed.ncbi.nlm.nih.gov/11697753
Publikováno v:
Pharmacotherapy. 21(10)
Study Objective. To determine the pharmacokinetic parameters of the components of gemtuzumab ozogamicin and to assess the possible influence of age and gender on the values. Design. Phase II, multicenter, open-label, nonrandomized, parallel study. Se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1dd502a09059d57fb3d5c9bad40b3f
https://pubmed.ncbi.nlm.nih.gov/11601662
https://pubmed.ncbi.nlm.nih.gov/11601662
Publikováno v:
Journal of clinical pharmacology. 38(3)
Modafinil is a novel wake-promoting agent being developed for treatment of excessive daytime sleepiness associated with narcolepsy. An open, 3 x 3 Latin square, randomized, cross-over study was performed in healthy males to compare the pharmacokineti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef763e375e0e35e6ff13fd74727f77cd
https://pubmed.ncbi.nlm.nih.gov/9549666
https://pubmed.ncbi.nlm.nih.gov/9549666